4-Methoxy-2,3-dimethyl-benzol-sulfonamid-(1) | 90643-83-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Methoxy-2,3-dimethyl-benzol-sulfonamid-(1)
• 英文别名: 4-Methoxy-2,3-dimethylbenzenesulfonamide
• CAS: 90643-83-7
• 化学式: C₉H₁₃NO₃S
• mdl: MFCD11106133
• 分子量: 215.273
• InChiKey: GGVNFYLQCOFUNX-UHFFFAOYSA-N

物化性质

• 熔点：
  180-183 °C
• 沸点：
  388.0±52.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  77.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'IMIDAZOLYL KINASE ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016014542A1

  公开（公告）日：2016-01-28

  The present disclosure provides imidazolyl compounds of Formula (I) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e.g., proliferative disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

  本公开提供了公式(I)的咪唑啉化合物及其制备方法。所提供的化合物能够结合蛋白激酶，并且可能在调节（例如，抑制）主体或细胞中的蛋白激酶活性以及/或在需要治疗的主体中治疗或预防疾病（例如，增殖性疾病、遗传性疾病、血液病、神经病、疼痛状况、精神障碍或代谢障碍）方面有用。此外，还提供了包括或涉及本文所述化合物的药物组合物、试剂盒、方法和用途。
• [EN] O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA O-GLCNAC TRANSFÉRASE ET LEURS UTILISATIONS
  申请人：HARVARD COLLEGE

  公开号：WO2020047251A1

  公开（公告）日：2020-03-05

  Provided herein are O-GlcNAc transferase (OGT) inhibitor compounds of Formula (I'), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., diabetes and complications thereof, neurodegenerative diseases, proliferative diseases such as cancers, autoimmune diseases, and inflammatory diseases) in a subject. Provided are methods of inhibiting OGT in a subject or biological sample.

  本发明提供了O-葡萄糖醛酸转移酶（OGT）抑制化合物，其化学公式为（I'），以及药用可接受的盐、溶剂化物、水合物、多晶型、共晶、互变异构体、对映异构体、同位素标记衍生物、前药和由其组成的组合物。还提供了涉及本发明的化合物或组合物用于治疗和/或预防受试者疾病（例如，糖尿病及其并发症、神经退行性疾病、增殖性疾病如癌症、自身免疫病和炎症性疾病）的方法和试剂盒。还提供了在受试者或生物样本中抑制OGT的方法。
• [EN] STABILIZED TRIOXACARCIN ANTIBODY DRUG CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS MÉDICAMENT TRIOXACARCINE-ANTICORPS STABILISÉS ET UTILISATIONS DE CEUX-CI
  申请人：HARVARD COLLEGE

  公开号：WO2021252708A1

  公开（公告）日：2021-12-16

  Provided herein are antibody drug conjugates of Formula (I): G-R7(I) and pharmaceutically acceptable salts thereof, wherein G is a molecular payload; and R7 is - L-A-B, wherein L is a linking group, A is a conjugating group, and B is an antibody or antibody fragment. Also provided are methods of preparing the antibody-drug conjugates, pharmaceutically acceptable compositions thereof, and methods of their use and treatment. Further provided are precursors to the antibody drug conjugates (e.g., compounds of Formula (III), novel trioxacarcins without an antibody conjugated thereto), pharmaceutical compositions thereof, and methods of their use and treatment.

  提供的是公式(I)的抗体药物偶联物：G-R7(I)及其药用可接受的盐，其中G是分子有效载荷；R7是-L-A-B，其中L是连接基团，A是偶联基团，B是抗体或抗体片段。还提供了制备抗体-药物偶联物的方法，药用可接受的组合物，以及其使用和治疗方法。还提供了抗体药物偶联物的前体（例如，公式(III)的化合物，没有抗体偶联的新型三氧杂卡菌素），其药用组合物，以及其使用和治疗方法。
• [EN] 14-MEMBERED KETOLIDES AND METHODS OF THEIR PREPARATION AND USE<br/>[FR] KÉTOLIDES À 14 CHAÎNONS ET LEURS PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：HARVARD COLLEGE

  公开号：WO2016057798A1

  公开（公告）日：2016-04-14

  Provided herein are methods of preparing new 14-membered ketolides via coupling of an eastern and western half moiety, followed by macrocyclization, and optional functionalization. Intermediates in the synthesis of these ketolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using these ketolides are also provided.

  本文提供了一种制备新的14元环酮类化合物的方法，通过将东半部分和西半部分偶联，然后进行大环化，以及可选的官能化。还提供了合成这些酮类化合物的中间体，包括东部和西部部分。还提供了使用这些酮类化合物治疗传染病和炎症性疾病的药物组合物和方法。
• [EN] ANALOGS OF YOHIMBINE AND USES THEREOF<br/>[FR] ANALOGUES DE LA YOHIMBINE ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2017190038A1

  公开（公告）日：2017-11-02

  The present disclosure provides compounds of Formulae (I-A), (ΙI'), (III-A), (IV'), and (V-A), wherein the compounds are derived from or based on yohimbine. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, cancers, inflammatory diseases, autoimmune diseases, and infectious diseases) in a subject in need thereof. The present disclosure provides methods of preparing compounds of Formulae (I-A), (ΙI'), (III-A), (IV'), and (V-A). Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

  本公开提供了公式(I-A)、(ΙI')、(III-A)、(IV')和(V-A)的化合物，其中这些化合物源自或基于醉茄碱。所提供的化合物可能在治疗或预防疾病（如增生性疾病、癌症、炎症性疾病、自身免疫性疾病和传染病）的患者中具有用处。本公开提供了制备公式(I-A)、(ΙI')、(III-A)、(IV')和(V-A)化合物的方法。还提供了包括或涉及本文描述的化合物的药物组合物、试剂盒、方法和用途。